EBITDA: Income before interest, taxes, depreciation and amortization.
Spyre Therapeutics, Inc. (SYRE) had EBITDA of $-56.89M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-11.18M |
|
-- |
|
-- |
|
$56.89M |
|
$-56.89M |
|
$45.70M |
|
$-11.18M |
|
$-11.18M |
|
$-11.18M |
|
$-11.18M |
|
$-11.18M |
|
$-11.18M |
|
$-56.89M |
|
|
EBITDA |
$-56.89M |
60.41M |
|
60.41M |
|
$-0.15 |
|
$-0.15 |
|
| Balance Sheet Financials | |
$504.60M |
|
-- |
|
-- |
|
$504.60M |
|
$46.27M |
|
-- |
|
$3.23M |
|
$49.50M |
|
$299.28M |
|
$455.10M |
|
$455.10M |
|
60.47M |
|
| Cash Flow Statement Financials | |
$-124.67M |
|
$103.94M |
|
$-3.79M |
|
$89.42M |
|
$64.90M |
|
$-24.53M |
|
$27.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.90 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-124.67M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-3.74% |
|
-2.46% |
|
-2.22% |
|
-2.46% |
|
$7.53 |
|
$-2.06 |
|
$-2.06 |
|